Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001104659-20-134972
Filing Date
2020-12-14
Accepted
2020-12-14 06:05:37
Documents
1
Group Members
CASEY M. TANSEYJONATHAN D. ROOTPRESIDIO MANAGEMENT GROUP XII, L.L.CU.S. VENTURE PARTNERS XII-A, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D tm2038319d1_sc13d.htm SC 13D 133319
  Complete submission text file 0001104659-20-134972.txt   134982
Mailing Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109
Business Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109 206-456-2900
Silverback Therapeutics, Inc. (Subject) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91894 | Film No.: 201385001
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1460 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025
Business Address 1460 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 (650) 854-9080
U.S. Venture Partners XII, L.P. (Filed by) CIK: 0001734819 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D